References

References

  1. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, Greenspan FS, McDougall IR, Nikolai TF 1995 Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA 273:808–812.
  2. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, Segal RL; American Association of Clinical Endocrinologists 2002 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 6:457–469.
  3. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O’Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT, Varonen H, Vist GE, Williams JW Jr., Zaza S; GRADE Working Group 2004 Grading quality of evidence and strength of recommendations. BMJ 328:1490.
  4. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schünemann H 2006 Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest 129:174–181.
  5. Mechanick JI, Camacho PM, Cobin RH, Garber AJ, Garber JR, Gharib H, Petak SM, Rodbard HW, Trence DL; American Association of Clinical Endocrinologists 2010 American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines— 2010 update. Endocr Pract 16:270–283
  6. Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM 2008 A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 93:666–673..
  7. Berghout A, Wiersinga WM, Smits NJ, Touber JL 1990 Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. Am J Med 89:602–608.
  8. Gozu HI, Lublinghoff J, Bircan R, Paschke R 2010 Genetics and phenomics of inherited and sporadic non-autoimmune hyperthyroidism. Mol Cell Endocrinol 322:125–134.
  9. Martin FI, Deam DR 1996 Hyperthyroidism in elderly hospitalised patients. Clinical features and outcome. Med J Aust 164:200–203.
  10. Davis PJ, Davis FB 1974 Hyperthyroidism in patients over the age of 60 years. Clinical features in 85 patients. Medicine (Baltimore) 53:161–181.
  11. Tibaldi JM, Barzel US, Albin J, Surks M 1986 Thyrotoxicosis in the very old. Am J Med 81:619–622.
  12. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G 1991 High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 229:415–420.
  13. Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P 1988 Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J Clin Endocrinol Metab 67:656–662.
  14. Williams I, Ankrett VO, Lazarus JH, Volpe R 1983 Aetiology of hyperthyroidism in Canada and Wales. J Epidemiol Community Health 37:245–248.
  15. Gerstein HC 1990 How common is postpartum thyroiditis? A methodologic overview of the literature. Arch Intern Med 150:1397–1400.
  16. Miller KK, Daniels GH 2001 Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol (Oxf ) 55:501–508.
  17. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, Salvi M, Fiaccadori F, Ugolotti G, Neri TM, Braverman LE 1996 Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 101:482–487.
  18. Cohen-Lehman J, Dahl P, Danzi S, Klein I 2010 Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinology 6:34–41.
  19. Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ 2003 Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab 88:2100–2105.
  20. Klein I, Danzi S 2007 Thyroid disease and the heart. Circulation 116:1725–1735.
  21. Burch HB, Wartofsky L 1993 Life-threatening hyperthyroidism: thyroid storm. Endocrinol Metab Clin North Am 22:263–277.
  22. Hall P, Lundell G, Holm LE 1993 Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinol (Cph) 128:230–234.
  23. Trzepacz PT, McCue M, Klein I, Levey GS, Greenhouse J 1988 A psychiatric and neuropsychological study of patients with untreated Graves' disease. Gen Hosp Psychiatry 10:49–55.
  24. Trzepacz PT,Klein I, Roberts M,Greenhouse J, Levey GS 1989 Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 87:558–561.
  25. Boelaert K, Torlinska B, Holder RL, Franklyn JA 2010 Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. JCEM 95:2715–2726.
  26. Ventrella S, Klein I 1994 Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. The Endocrinologist 4:391–399.
  27. European Heart Rhythm Association; Heart Rhythm Society, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr., Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation 2006 ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol 48:854–906.
  28. Brennan MD, Coenen-Schimke JM, Bigelow ML, Nair KS 2006 Changes in skeletal muscle protein metabolism and myosin heavy chain isoform messenger ribonucleic acid abundance after treatment of hyperthyroidism. J Clin Endocrinol Metab 91:4650–4656.
  29. de los Santos ET, Starich GH, Mazzaferri EL 1989 Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med 149:526–532.
  30. Spencer CA, LoPresti JS, Patel A, Guttler RB, Eigen A, Shen D, Gray D, Nicoloff JT 1990 Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab 70:453–460.
  31. Rajatanavi R, Braverman LE 1983 Euthyroid hyperthyroxinemia. J Endocrinol Invest 6:493–505.
  32. Rajatanavin R, Liberman C, Lawrence GD, D'Arcangues CM, Young RA, Emerson CH 1985 Euthyroid hyperthyroxinemia and thyroxine-binding prealbumin excess in islet cell carcinoma. J Clin Endocrinol Metab 61:17–21.
  33. Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, Stevenaert A, Beckers A 2003 The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 148: 433–442.
  34. Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs E, Weintraub BD 1995 Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med 123:572–583.
  35. Summaria V, Salvatori M, Rufini V, Mirk P, Garganese MC, Romani M 1999 Diagnostic imaging in thyrotoxicosis. Rays 24:273–300.
  36. Bogazzi F, Vitti P 2008 Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nat Clin Pract Endocrinol Metab 4:70–71.
  37. Shigemasa C, Abe K, Taniguchi S, Mitani Y, Ueda Y, Adachi T, Urabe K, Tanaka T, Yoshida A, Mashiba H 1987 Lower serum free thyroxine (T4) levels in painless thyroiditis compared with Graves' disease despite similar serum total T4 levels. J Clin Endocrinol Metab 65:359– 363.
  38. Woolf PD 1980 Transient painless thyroiditis with hyperthyroidism: a variant of lymphocytic thyroiditis? Endocr Rev 1:411–420.
  39. Mariotti S, Martino E, Cupini C, Lari R, Giani C, Baschieri L, Pinchera A 1982 Low serum thyroglobulin as a clue to the diagnosis of hyperthyroidism factitia. N Engl J Med 307:410–412.
  40. Bouillon R, Verresen L, Staels F, Bex M, De Vos P, De Roo M 1993 The measurement of fecal thyroxine in the diagnosis of thyrotoxicosis factitia. Thyroid 3:101–103.
  41. Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D, Poertl S, Weglo¨hner W, Hollidt JM, Quadbeck B, Dumont JE, Schumm-Draeger PM, Bergmann A, Mann K, Vassart G, Usadel KH 1999 Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab 84:90–97.
  42. Paunkovic J, Paunkovic N 2006 Does autoantibody-negative Graves' disease exist? A second evaluation of the clinical diagnosis. Horm Met Res 38:53–56.
  43. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P 2001 TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol (Oxf ) 55:381–390.
  44. Klein I, Becker D, Levey GS 1994 Treatment of hyperthyroid disease. Ann Int Med 121:281–288.
  45. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M 1991 Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1:129–135.
  46. Abraham-Nordling M, Törring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, Wallin G 2005 Graves’ disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 15:1279–1286. .
  47. Weingold AB 1983 Appendicitis in pregnancy. Clin Obstet Gynecol 26:801–809.
  48. Kuy SR, Roman SA, Desai R, Sosa JA 2009 Outcomes following thyroid and parathyroid surgery in pregnant women. Arch Surg 144:399–406.
  49. Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nystrom E, Ponjavic V, Taube A, Torring O, Wallin G, Asman P, Lundell G; Thyroid Study Group of TT 96 2009 Thyroid-Associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine- 131. J Clin Endocrinol Metab 94:3700–3707.
  50. McDermott MT, Kidd GS, Dodson LE Jr., Hofeldt FD 1983 Radioiodine-induced thyroid storm. Case report and literature review. Am J Med 75:353–359.
  51. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Müller-Brand J, Müller B 2007 Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 334:514. .
  52. Delit C, Silver S, Yohalem SB, Segal RL 1961 Thyrocardiac disease and its management with radioactive iodine I-131. JAMA 176:262–267.
  53. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R 2001 The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. J Clin Endocrinol Metab 86:3016–3021.
  54. Andrade VA, Gross JL, Maia AL 1999 Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism. J Clin Endocrinol Metab 84:4012–4016.
  55. Klein I 2008 Endocrine disorders and cardiovascular disease. In: Libby P et al. (eds) Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 8th edition. Saunders/ Elsevier, Philadelphia, PA, pp 2033–2047.
  56. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P 1998 Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 338:712–718.
  57. Turner JG, Brownlie BE, Rogers TG 1976 Lithium as an adjunct to radioiodine therapy for thyrotoxicosis. Lancet 1:614–615.
  58. Bogazzi F, Bartalena L, Brogioni S, Scarcello G, Burelli A, Campomori A, Manetti L, Rossi G, Pinchera A, Martino E 1999 Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab 84:499–503.
  59. Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, Rossi G, Ceccarelli C, Vitti P, Pinchera A, Bartalena L, Martino E 2010 Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab 95:201–208.
  60. Von Hofe SE, Dorfman SG, Carretta RF, Young RL 1978 The increasing incidence of hypothyroidism within one year after radioiodine therapy for toxic diffuse goiter. J Nucl Med 19:180–184.
  61. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H 1995 Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131 iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 25:186–193.
  62. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA 2003 A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 88:978–983.
  63. Jarløv AE, Nygaard B, Hegedus L, Hartling SG, Hansen JM 1998 Observer variation in the clinical and laboratory evaluation of patients with thyroid dysfunction and goiter. Thyroid 8:393–398.
  64. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H 1996 Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study. Eur J Clin Invest 26:59–63.
  65. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H 1997 Treatment of Graves' hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid 7:247–251.
  66. Kaptein EM, Levenson H, Siegel ME, Gadallah M, Akmal M 2000 Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. J Clin Endocrinol Metab 85:3058–3064.
  67. Santos RB, Romaldini JH, Ward LS 2004 Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid 14:525– 530.
  68. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD Jr. 1998 Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 280:347–355.
  69. Sheline GE, Lindsay S, McCormack KR, Galante M 1962 Thyroid nodules occurring late after treatment of thryotoxicosis with radioiodine. J Clin Endocrinol Metab 22:8–18.
  70. New England Congenital Hypothyroidism Collaborative 1990 Elementary school performance of children with congenital hypothyroidism. J Pediatr 116:27–32.
  71. Franklyn JA, Sheppard MC, Maisonneuve P 2005 Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 294:71–80.
  72. Goldman MB, Monson RR, Maloof F 1990 Cancer mortality in women with thyroid disease. Cancer Res 50:2283–2289.
  73. Holm LE, Hall P, Wiklund K, Lundell G, Berg G, Bjelkengren G, Cederquist E, Ericsson UB, Hallquist A, Larsson LG, et al. 1991 Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 83:1072–1077.
  74. Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P 2007 Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 109:1972–1979.
  75. Ceccarelli C, Canale D, Battisti P, Caglieresi C, Moschini C, Fiore E, Grasso L, Pinchera A, Vitti P 2006 Testicular function after 131I therapy for hyperthyroidism. Clin Endocrinol (Oxf ) 65:446–452.
  76. Fisher WD, Voorhess ML, Gardner LI 1963 Congenital hypothyroidism in infant following maternal I-131 therapy with a review of hazards of environmental radioisotope contamination. J Pediatr 62:132–146.
  77. Berg GE, Nystrom EH, Jacobsson L, Lindberg S, Lindstedt RG, Mattsson S, Niklasson CA, Nore´n AH, Westphal OG 1998 Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med 39:357–361.
  78. Woodings S 2004 Radiation protection recommendations for I-131 thyrotoxicosis, thyroid cancer and phaeochromocytoma patients. Australas Phys Eng Sci Med 27:118–128.
  79. Uy HL, Reasner CA, Samuels MH 1995 Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease. Am J Med 99:173–179.
  80. Alexander EK, Larsen PR 2002 High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 87:1073–1077.
  81. Cooper DS 2005 Antithyroid drugs. N Engl J Med 352: 905–917.
  82. Cooper DS 1985 Propylthiouracil levels in hyperthyroid patients unresponsive to large doses. Evidence of poor patient compliance. Ann Intern Med 102:328–331.
  83. Cooper DS 2003 Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 88: 3474–3481.
  84. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS 2005 A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endorinol 153:489–498.
  85. Andersohn F, Konzen C, Garbe E 2007 Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146:657–665.
  86. Meyer-Gessner M, Benker G, Lederbogen S, Olbricht T, Reinwein D 1994 Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest 17:29–36.
  87. Kang AY, Baek YH, Sohn YJ, Lee SK, Son CH, Kim K, Yang DK 2006 Diffuse alveolar hemorrhage associated with antineutrophil cytoplasmic antibody levels in a pregnant woman taking propylthiouracil. Korean J Intern Med 21:240–243.
  88. Noh JY, Yasuda S, Sato S, Matsumoto M, Kunii Y, Noguchi Y, Mukasa K, Ito K, Ito K, Sugiyama O, Kobayashi H, Nihojima S, Okazaki M, Yokoyama S 2009 Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. J Clin Endocrinol Metab 94:2806–2811.
  89. Cin MO, Gursoy A, Morris Y, Aydintug OT, Kamel N, Gullu S 2009 Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves' patients treated with propylthiouracil. Int J Clin Pract 63:299–302.
  90. Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A 2000 Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 142:587.
  91. Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA 2003 Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 37:224–228.
  92. Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN 2009 The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19:673–674.
  93. FDA U.S. Food and Drug Administration information for healthcare professionals—propylthiouracil-induced liver failure 2009 Available at  www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm162701 .htm, accessed March 15, 2011.
  94. Vilchez FJ, Toores I, Garcia-Valero A, Lopez-Tinoco C, de Los Santos A, Aguilar-Diosdado M 2006 Concomitant agranulocytosis and hepatotoxicity after treatment with carbimazole. Ann Pharmacother 40:2059–2063.
  95. Woeber KA 2002 Methimazole-induced hepatotoxicity. Endocr Pract 8:222–224.
  96. Shivakumar SK, Dwarakanath S, Swaroop G, Venkataramana NK 2006 Aplasia cutis congenita of the scalp: therapeutic modalities. Neurol India 54:312–313.
  97. Wolf D, Foulds N, Daya H 2006 Antenatal carbimazole and choanal atresia: a new embryopathy. Arch Otolaryngol Head Neck Surg 132:1009–1011.
  98. Clark SM, Saade GR, Snodgrass WR, Hankins GD 2006 Pharmacokinetics and pharmacotherapy of thionamides in pregnancy. Ther Drug Monit 28:477–483.
  99. UpToDate patient information: antithyroid drugs. Available at  www.uptodate.com/patients/content/topic.do?topicKey =~K7dgOAIby0pAB7&source=see_link, accessed March 16, 2011.
  100. Tajiri J, Noguchi S, Murakami T, Murakami N 1990 Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 150:621–624.
  101. Ahmed K, Rao S, Simha V 2010 ANCA-positive vasculitis in a patient with Graves' disease: cross-reaction between propylthiouracil and methimazole. Endocr Pract 9:1–11.
  102. Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ 1993 Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med 118:424–428.
  103. Benyounes M, Sempoux C, Daumerie C, Rahier J, Geubel AP 2006 Propylthiouracyl-induced severe liver toxicity: an indication for alanine aminotransferase monitoring? World J Gastroenterol 12:6232–6234.
  104. Kim HJ, Kim BH, Han YS, Yang I, Kim KJ, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R 2001 The incidence and clinical characteristics of symptomatic propylthiouracilinduced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol 96: 165–169.
  105. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N 2007 Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 92:2157–2162.
  106. Weiss M, Hassin D, Bank H 1980 Propylthiouracil-induced hepatic damage. Arch Intern Med 140:1184–1185.
  107. Waseem M, Seshadri KG, Kabadi UM 1998 Successful outcome with methimazole and lithium combination therapy for propylthiouracil-induced hepatotoxicity. Endocr Pract 4:197–200.
  108. Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M 2008 Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 31:866–872.
  109. Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR 2002 Does smoking increase relapse rates in Graves' disease? J Endocrinol Invest 25:152–157.
  110. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA 2000 Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 85:1038–1042.
  111. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S 2002 Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol 147:583–589.
  112. Orunesu E, Bagnasco M, Salmaso C, Altrinetti V, Bernasconi D, Del Monte P, Pesce G, Marugo M, Mela GS 2004 Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdrawal. Eur J Clin Invest 34:210–217.
  113. Bolanos F, Gonzalez-Ortiz M, Duron H, Sanchez C 2002 Remission of Graves' hyperthyroidism treated with methimazole. Rev Invest Clin 54:307–310.
  114. Orgiazzi J, Madec AM 2002 Reduction of the risk of relapse after withdrawal of medical therapy for Graves' disease. Thyroid 12:849–853.
  115. Glinoer D, de Nayer P, Bex M; Belgian Collaborative Study Group on Graves' Disease 2001 Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 144:475–483.
  116. Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A 2000 Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Thyroid 10:891–896.
  117. Laurberg P, Buchholtz Hansen PE, Iversen E, Eskjaer Jensen S, Weeke J 1986 Goitre size and outcome of medical treatment of Graves' disease. Acta Endocrinol (Cph) 111:39–43.
  118. Erbil Y, Ozluk Y, Giris¸ M, Salmaslioglu A, Issever H, Barbaros U, Kapran Y, Ozarmag˘an S, Tezelman S 2007 Effect of Lugol solution on thyroid gland, blood flow and micovessel density in patients with Graves' disease. J Clin Endocrinol Metab 92:2182–2189.
  119. Ansaldo GL, Pretolesi F, Varaldo E, Meola C, Minuto M, Borgonovo G, Derchi LE, Torre GC 2000 Doppler evaluation of intrathyroid arterial resistances during preoperative treatment with Lugol's iodide solution in patients with diffuse toxic goiter. J Am Coll Surg 191:607–612.
  120. A Baeza A, Aguayo J, Barria M, Pineda G 1991 Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf ) 35:439–442.
  121. Palit TK, Miller CC 3rd, Miltenburg DM 2000 The efficacy of thyroidectomy for Graves; disease: a meta-analysis. J Surg Res 90:161–165.
  122. Sosa JA, Mehta PJ, Wang TS, Boudourakis L, Roman SA 2008 A population based study of outcomes from thyroidectomy in aging Americans: at what cost? J Am Coll Surg 206:1097–1105.
  123. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R 1998 The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 228:320–330.
  124. Roher HD, Goretzki PE, Hellmann P, Witte J 1999 Complications in thyroid surgery. Incidence and therapy. Chirurg 70:999–1010.
  125. Abbas G, Dubner S, Heller KS 2001 Re-operation for bleeding after thyroidectomy and parathyroidectomy. Head Neck 23:544–546.
  126. Jenkins K, Baker AB 2003 Consent and anaesthetic risk. Anaesthesia 58:962–984.
  127. Husein M, Hier MP, Al-Abdulhadi K, Black M 2002 Predicting calcium status post-thyroidectomy with early calcium levels. Otolaryngol Head Neck Surg 127:289–293.
  128. Sywak MS, Palazzo FF, Yeh M, Wilkinson M, Snook K, Sidhu SB, Delbridge LW 2007 Parathyroid hormone assay predicts hypocalcaemia after total thyroidectomy. Anz J Surg 77:667–670.
  129. Wiseman JE, Mossanen M, Ituarte PH, Bath JM, Yeh MW 2010 An algorithm informed by the parathyroid hormone level reduces hypocalcemic complications of thyroidectomy. World J Surg 34:532–537.
  130. Sabour S, Manders E, Steward DL 2009 The role of rapid PACU parathyroid hormone in reducing post-thyroidectomy hypocalcemia. Otolaryngol Head Neck Surg 141:727–729.
  131. Jumaily JS, Noordzij JP, Dukas AG, Lee SL, Bernet VJ, Payne RJ, McLeod IK, Hier MP, Black MJ, Kerr PD, Raffaelli M, Bellantone R, Lombardi CP, Dietrich MS 2010 Prediction of hypocalcemia after using 1- to 6-hour postoperative parathyroid hormone and calcium levels: an analysis of pooled individual patient data from 3 observational studies. Head Neck 32:427–434.
  132. McLeod IK, Arciero C, Noordzij JP, Stojadinovic A, Peoples G, Melder PC, Langley R, Bernet V, Shriver CD 2006 The use of rapid parathyroid hormone assay in predicting postoperative hypocalcemia after total or completion thyroidectomy. Thyroid 16:259–265.
  133. Kaplan EL, Angelos P 2006 Thyroid disease manager. Surgery of the thyroid gland. Available at  www.thyroidmanager.org/ Chapter21/21-frame.htm, accessed May 18, 2010.
  134. Noordzij JP, Lee SL, Bernet VJ, Payne RJ, Cohen SM, McLeod IK, Hier MP, Black MJ, Kerr PD, Richards ML, Lo CY, Raffaelli M, Bellantone R, Lombardi CP, Cohen JI, Dietrich MS 2007 Early prediction of hypocalcemia after thyroidectomy using parathyroid hormone: an analysis of pooled individual patient data from nine observational studies. J Am Coll Surg 205:748–754.
  135. Cote V, Sands N, Hier MP, Black MJ, Tamilia M, MacNamara E, Zhang X, Payne RJ 2008 Cost savings associated with post-thyroidectomy parathyroid hormone levels. Otolaryngol Head Neck Surg 138:204–208.
  136. Bellantone R, Lombardi CP, Raffaelli M, Boscherini M, Alesina PF, De Crea C, Traini E, Princi P 2002 Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy? Surgery 132:1109–1113.
  137. Wilson RB, Erskine C, Crowe PJ 2000 Hypomagnesemia and hypocalcemia after thyroidectomy: prospective study. World J Surg 24:722–726.
  138. Roh JL, Park CI 2006 Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy. Am J Surg 192:675–678.
  139. Stocker DJ, Burch HB 2003 Thyroid cancer yield in patients with Graves' disease. Minerva Endocrinol 28:205–212.
  140. Kikuchi S, Noguchi S, Yamashita H, Uchino S, Kawamoto H 2006 Prognosis of small thyroid cancer in patients with Graves' disease. Br J Surg 93:434–439.
  141. Cappelli C, Pirola I, De Martino E, Agosti B, Delbarba A, Castellano M, Rosei EA 2007 The role of imaging in Graves' disease: a cost-effectiveness analysis. Eur J Radiol 65:99–103.
  142. Cakir M, Arici C, Alakus H, Altunbas H, Balci MK, Karayalcin U 2007 Incidental thyroid carcinoma in thyrotoxic patients treated by surgery. Horm Res 67:96–99.
  143. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ,Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214.
  144. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedu¨ s L, Vitti P; AACE/AME/ETA Task Force on Thyroid Nodules 2010 American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 16:468–475.
  145. Nayak B, Burman K 2006 Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 35:663–686.
  146. Roti E, Robuschi G, Gardini E, Montermini M, Salvi M, Manfredi A, Gnudi A, Braverman LE 1988 Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease. Clin Endocrinol (Oxf ) 28:305–314.
  147. Erickson D, Gharib H, Li H, van Heerden JA 1998 Treatment of patients with toxic multinodular goiter. Thyroid 8:277–282.
  148. Kang AS, Grant CS, Thompson GB, van Heerden JA 2002 Current treatment of nodular goiter with hyperthyroidism (Plummer's disease): surgery versus radioiodine. Surgery 132:916–923.
  149. Nygaard B, Hegedu¨ s L, Ulriksen P, Nielsen KG, Hansen JM 1999 Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 159:1364–1368.
  150. Holm LE, Lundell G, Israelsson A, Dahlqvist I 1982 Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J Nucl Med 23:103–107.
  151. Vidal-Trecan GM, Stahl JE, Eckman MH 2004 Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid 14:933–945.
  152. Nygaard B, Hegedus L, Nielsen KG, Ulriksen P, Hansen JM 1999 Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf ) 50:197–202.
  153. Vaiman M, Nagibin A, Hagag P, Kessler A, Gavriel H 2008 Hypothyroidism following partial thyroidectomy. Otolaryngol Head Neck Surg 138:98–100.
  154. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A 2005 Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study. Clin Endocrinol (Oxf ) 62:331–335.
  155. Goldstein R, Hart IR 1983 Follow-up of solitary autonomous thyroid nodules treated with 131I. N Engl J Med 309:1473–1476.
  156. Porterfield JR Jr., Thompson GB, Farley DR, Grant CS, Richards ML 2008 Evidence-based management of toxic multinodular goiter (Plummer's disease). World J of Surg 32:1278–1284.
  157. Bonnema SJ, Bertelsen H, Mortensen J, Andersen PB, Knudsen DU, Bastholt L, Hegedus I 1999 The feasibility of high dose iodine 131 as an alternative to surgery in patients with a very large goiter; effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 84:3636–3641.
  158. Wahl RA, Rimpl I, Saalabian S, Schabram J 1998 Differentiated operative therapy of thyroid autonomy (Plummer's disease). Exp Clin Endocrinol Diabetes 106: S78–S84.
  159. van Soestbergen MJ, van der Vijver JC, Graafland AD 1992 Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves' disease. J Endocrinol Invest 15:797–800.
  160. Nygaard B, Faber J, Veje A, Hegedu¨ s L, Hansen JM 1999 Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by I131 therapy. Thyroid 9:477–481.
  161. Hall P, Berg G, Bjelkengren G, Boice JD Jr., Ericsson UB, Hallquist A, Lidberg M, Lundell G, Tennvall J, Wiklund K, et al. 1992 Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer 50:886–890.
  162. Becker DV, Hurley JR 1971 Complications of radioiodine treatment of hyperthyroidism. Semin Nucl Med 1:442– 460.
  163. Braverman L, Kloos RT, Law B Jr., Kipnes M, Dionne M, Magner J 2008 Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract 14:832–839.
  164. Koornstra JJ, Kerstens MN, Hoving J, Visscher KJ, Schade JH, Gort HB, Leemhuis MP 1999 Clinical and biochemical changes following 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs. Neth J Med 55:215–221.
  165. Cerci C, Cerci SS, Eroglu E, Dede M, Kapucuoglu N, Yildiz M, Bulbul M 2007 Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med 53:157–160.
  166. Ferrari C, Reschini E, Paracchi A 1996 Treatment of the autonomous thyroid nodule: a review. Eur J Endocrinol 135:383–390.
  167. Albino CC, Graf H, Sampaio AP, Viga´rio A, Paz-Filho GJ 2008 Thiamazole as an adjuvant to radioiodine for volume reduction of multinodular goiter. Expert Opin Investig Drugs 17:1781–1786.
  168. Magner J 2008 Problems associated with the use of thyrogen in patients with a thyroid gland. N Engl J Med 359: 1738–1739.
  169. Zakavi SR, Mousavi Z, Davachi B 2009 Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule. Nucl Med Commun 30:169–175.
  170. Dobyns BM 1978 Prevention and management of hyperthyroid storm. World J Surg 2:293–306.
  171. Hamilton WF, Forrest AL, Gunn A, Peden NR, Feely J 1984 Beta-adrenoceptor blockade and anaesthesia for thyroidectomy. Anaesthesia 39:335–342.
  172. Fleisher LA 2000 Risk of anesthesia. In: Miller RD (ed) Anesthesia, 5th edition. Churchill Livingstone, Philadelphia, PA, pp 795–823.
  173. Spanknebel K, Chabot JA, DiGiorgi M, Cheung K, Lee S, Allendorf J, Logerfo P 2005 Thyroidectomy using local anesthesia: a report of 1,025 cases over 16 years. J Am Coll Surg 201:375–385.
  174. Siegel RD, Lee SL 1998 Toxic nodular goiter: toxic adenoma and toxic multinodular goiter. Endocrinol Metab Clin N Am 27:151–168.
  175. Reeve TS, Delbridge L, Cohen A, Crummer P 1987 Total thyroidectomy. The preferred option for multinodular goiter. Ann Surg 203:782–786.
  176. Mishra A, Agarwal A, Agarwal G, Mishra SK 2001 Total thyroidectomy for benign thyroid disorders in an endemic region. World J Surg 25:307–310.
  177. Pappalardo G, Guadalaxara A, Frattaroli FM, Illomei G, Falaschi P 1998 Total compared with subtotal thyroidectomy in benign nodular disease: personal series and review of published reports. Eur J Surg 164:501–506.
  178. Hisham AN, Azlina AF, Aina EN, Sarojah A 2001 Total thyroidectomy: the procedure of choice for multinodular goitre. Eur J Surg 167:403–405.
  179. al-Suliman NN, Ryttov NF, Qvist N, Blichert-Toft M, Graversen HP 1997 Experience in a specialist thyroid surgery unit; a demographic study, surgical complications, and outcome. Eur J Surg 163:13–20.
  180. Thomusch O, Machens A, Sekulla C, Ukkat J, Lippert H, Gastinger I, Dralle H 2000 Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg 24:1335–1341.
  181. Bliss R, Patel N, Guinea A, Reeve TS, Delbridge L 1999 Age is no contraindication to thyroid surgery. Age Ageing 28:363–366.
  182. Sosa JA, Mehta PJ, Wang TS, Yeo HL, Roman SA 2007 Racial disparities in clinical and economic outcomes from thyroidectomy. Ann Surg 246:1083–1091.
  183. Takáts KI, Szabolcs I, Földes J, Földes I, Ferencz A, Rimanóczy E, Góth M, Dohán O, Kovács L, Szilágyi G 1999 The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goiter compared to radioiodine therapy with different doses. Exp Clin Endocrinol Diabetes 107:70–74..
  184. Tarantino L, Francica G, Sordelli I, Sperlongano P, Parmeggiani D, Ripa C, Parmeggiani U 2008 Percutaneous ethanol injection of hyperfunctioning thyroid nodules: long-term follow-up in 125 patients. AJR Am J Roentgenol 190:800–808.
  185. Monzani F, Caraccio N, Goletti O, Lippolis PV, Casolaro A, Del Guerra P, Cavina E, Miccoli P 1997 Five-year follow-up of percutaneous ethanol injection for the treatment of hyperfunctioning thyroid nodules: a study of 117 patients. Clin Endocrinol (Oxf ) 46:9–15.
  186. Zingrillo M, Modoni S, Conte M, Frusciante V, Trischitta V 2003 Percutaneous ethanol injection plus radioiodine versus radioiodine along in the treatment of large toxic thyroid nodules. J Nucl Med 44:207–210.
  187. Ma C, Kuang A, Xie J, Liu G 2008 Radioiodine treatment for pediatric Graves' disease. Cochrane Database Syst Rev 16:CD006294.
  188. Rivkees SA, Sklar C, Freemark M 1998 Clinical review 99: the management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 83:3767–3776.
  189. Levy WJ, Schumacher OP, Gupta M 1988 Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. Cleve Clin J Med 55:373–382.
  190. Lee JA, Grumbach MM, Clark OH 2007 The optimal treatment for pediatric Graves' disease is surgery. J Clin Endocrinol Metab 92:801–803.
  191. Freitas JE, Swanson DP, Gross MD, Sisson JC 1979 Iodine- 131: optimal therapy for hyperthyroidism in children and adolescents? J Nucl Med 20:847–850.
  192. Boice JD Jr. 2006 Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA 295:1060–1062.
  193. Boice JD Jr. 2005 Radiation-induced thyroid cancer—what's new? J Natl Cancer Inst 97:703–705.
  194. Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA 2008 Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 93:3058–3065.
  195. Tuggle CT, Roman SA, Wang TS, Boudourakis L, Thomas D, Udelsman R, Ann Sosa J 2008 Pediatric endocrine surgery: who is operating on our children? Surgery 144:869–877.
  196. Nicholas WC, Fischer RG, Stevenson RA, Bass JD 1995 Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J 88:973–976.
  197. Sato H, Harada S, Yokoya S, Tanaka T, Asayama K, Mori M, Sasaki N 2007 Treatment for childhood-onset Graves' disease in Japan: results of a nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. Thyroid 17:67–72.
  198. Cassio A, Corrias A, Gualandi S, Tato' L, Cesaretti G, Volta C, Weber G, Bona G, Cappa M, Bal M, Bellone J, Cicognani A 2006 Influence of gender and pubertal stage at diagnosis on growth outcome in childhood thyrotoxicosis: results of a collaborative study. Clin Endocrinol (Oxf ) 64:53–57.
  199. Dötsch J, Rascher W, Dorr HG 2003 Graves disease in childhood: a review of the options for diagnosis and treatment. Paediatr Drugs 5:95–102..
  200. Dötsch J, Siebler T, Hauffa BP, Doeker B, Andler W, Bettendorf M, Heinrich U, Gohlke B, Albers N, Willgerodt H, Kiess W 2000 Diagnosis and management of juvenile hyperthyroidism in Germany: a retrospective multicenter study. J Pediatr Endocrinol Metab 13:879–885..
  201. Mussa GC, Corrias A, Silvestro L, Battan E, Mostert M, Mussa F, Pellegrino D 1999 Factors at onset predictive of lasting remission in pediatric patients with Graves' disease followed for at least three years. J Pediatr Endocrinol Metab 12:537–541.
  202. Perrild H, Gruters-Kieslich A, Feldt-Rasmussen U, Grant D, Martino E, Kayser L, Delange F 1994 Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol 131:467–473.
  203. Slyper AH,Wyatt D, Boudreau C 2005 Effective methimazole dose for childhood Graves' disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidismand delayed pituitary recovery. J Pediatr Endocrinol Metab 18:597–602.
  204. Smith J, Brown RS 2007 Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication. Thyroid 17:1103–1107.
  205. Abraham P, Avenell A, Watson WA, Park CM, Bevan JS 2005 Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev 18:CD003420.
  206. Razvi S, Vaidya B, Perros P, Pearce SH 2006 What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol 154:783–786.
  207. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, Ridgway EC 1983 Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 98:26–29.
  208. Rivkees SA, Mattison DR 2009 Ending propylthiouracilinduced liver failure in children. N Engl J Med 360:1574– 1575.
  209. Rivkees SA, Mattison DR 2009 Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 2009:132041.
  210. Eunice Kennedy Shriver National Institute of Child Health and Human Development 2008 Conference Proceeding: Hepatic Toxicity Following Treatment for Pediatric Graves' Disease Meeting: October 28, 2008. Available at http:// bpca.nichd.nih.gov/outreach/index.cfm, accessed March 16, 2011.
  211. Salpeter SR, Ormiston TM, Salpeter EE 2002 Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 137:715–725.
  212. Rivkees SA, Stephenson K, Dinauer C 2010 Adverse events associated with methimazole therapy of graves' disease in children. Int J Pediatr Endocrinol 2010:176970.
  213. Hamburger JI 1985 Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 60:1019– 1024.
  214. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J; French Childhood Graves' Disease Study Group 2008 Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 93:3817– 3826.
  215. Tajiri J, Noguchi S 2005 Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy? Thyroid 15:292–297.
  216. Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M 2000 Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 85:3678–3682.
  217. Weetman AP 2006 Graves' hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? Nat Clin Pract Endocrinol Metab 2:2–3.
  218. Glaser NS, Styne DM; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group 2008 Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics 121:e481–e488.
  219. Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW 1997 Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 7:755–760.
  220. Lippe BM, Landaw EM, Kaplan SA 1987 Hyperthyroidism in children treated with long term medical therapy: twentyfive percent remission every two years. J Clin Endocrinol Metab 64:1241–1245.
  221. Glaser NS, Styne DM 1997 Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 82: 1719–1726.
  222. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O 2008 TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158:69–75.
  223. Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA 2001 Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab 86:1865–1867.
  224. Rivkees SA, Cornelius EA 2003 Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics 111:745–749.
  225. Bonnema SJ, Bennedbaek FN, Gram J, Veje A, Marving J, Hegedus L 2003 Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur J Endocrinol 149:485–492.
  226. Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA 2002 Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr 141:99–103.
  227. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV 1974 Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab 38: 976–998.
  228. Boice JD Jr. 1998 Radiation and thyroid cancer: what more can be learned? Acta Oncol 37:321–324.
  229. Dolphin GW 1968 The risk of thyroid cancers following irradiation. Health Phys 15:219–228.
  230. Rivkees SA, Dinauer C 2007 An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab 92:797–800.
  231. Ueda D 1990 Normal volume of the thyroid gland in children. J Clin Ultrasound 18:455–462.
  232. Kalinyak JE, McDougall IR 2003 How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism? J Clin Endocrinol Metab 88:975–977.
  233. Rivkees SA 2006 The treatment of Graves' disease in children. J Pediatr Endocrinol Metab 19:1095–1111.
  234. Rivkees SA 2007 Graves' disease therapy in children: truth and inevitable consequences. J Pediatr Endocrinol Metab 20:953–955.
  235. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr. 1995 Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141:259–277.
  236. Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD 2005 Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 365:2014–2023.
  237. Davis S, Kopecky KJ, Hamilton TE, Onstad L; Hanford Thyroid Disease Study Team 2004 Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the hanford nuclear site. JAMA 292:2600–2613.
  238. Dickman PW, Holm LE, Lundell G, Boice JD Jr., Hall P 2003 Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden. Int J Cancer 106:580–587.
  239. Shore RE 1992 Issues and epidemiological evidence regarding radiation-induced thyroid cancer. Radiat Res 131: 98–111.
  240. Read CH, Jr., Tansey MJ, Menda Y 2004 A 36 year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab 89:4229–4233.
  241. Toohey RE, Stabin MG, Watson EE 2000 The AAPM/ RSNA physics tutorial for residents: internal radiation dosimetry: principles and applications. Radiographics 20:533– 546.
  242. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation, Board on Radiation Effects, Research Division on Earth and Life Studies, National Research Council of the National Academies 2006 Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII–Phase 2. National Academies Press, Washington, DC.
  243. Miccoli P, Vitti P, Rago T, Iacconi P, Bartalena L, Bogazzi F, Fiore E, Valeriano R, Chiovato L, Rocchi R, Pinchera A 1996 Surgical treatment of Graves' disease: subtotal or total thyroidectomy? Surgery 120:1020–1024; discussion 1024– 1025.
  244. Sherman J, Thompson GB, Lteif A, Schwenk WF 2nd, van Heerden J, Farley DR, Kumar S, Zimmerman D, Churchward M, Grant CS 2006 Surgical management of Graves disease in childhood and adolescence: an institutional experience. Surgery 140:1056–1061; discussion 1061–1062.
  245. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE 2002 Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489–499.
  246. Diez JJ 2003 Hyperthyroidism in patients older than 55 years: an analysis of the etiology and management. Gerontology 49:316–323.
  247. Abraham-Nordling M, Törring O, Lantz M, Hallengren B, Ohrling H, Lundell G, Calissendorff J, Jörneskog G, Wallin G 2008 Incidence of hyperthyroidism in Stockholm, Sweden, 2003–2005. Eur J Endocrinol 158:823–827..
  248. Lewis GF, Alessi CA, Imperial JG, Refetoff S 1991 Low serum free thyroxine index in ambulating elderly is due to a resetting of the threshold of thyrotropin feedback suppression. J Clin Endocrinol Metab 73:843–849.
  249. Mariotti S, Barbesino G, Caturegli P, Bartalena L, Sansoni P, Fagnoni F, Monti D, Fagiolo U, Franceschi C, Pinchera A 1993 Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab 77:1130–1134.
  250. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC 1991 Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf ) 34:77–83.
  251. Bjørndal MM, Sandmo Wilhelmsen K, Lu T, Jorde R 2008 Prevalence and causes of undiagnosed hyperthyroidism in an adult healthy population. The Tromsø study. J Endocrinol Invest 31:856–860.
  252. Meyerovitch J, Rotman-Pikielny P, Sherf M, Battat E, Levy Y, Surks MI 2007 Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med 167:1533–1538.
  253. Woeber KA 2005 Observations concerning the natural history of subclinical hyperthyroidism. Thyroid 15:687–691.
  254. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249– 1252.
  255. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW 2006 Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295:1033–1041.
  256. Sgarbi JA, Villaca F, Garbeline B, Villar H E, Romaldini JH 2003 The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 88:1672–1677.
  257. Faber J, Wiinberg N, Schifter S, Mehlsen J 2001 Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol 145:391–396.
  258. Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Sacca` L, Filetti S, Lombardi G, Perticone F 2000 Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 85:4701–4705.
  259. Bauer DC, Ettinger B, Nevitt MC, Stone KL; Study of Osteoporotic Fractures Research Group 2001 Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134:561–568.
  260. Muddle AH, Houben AJ, Nieuwenhuijzen Kruseman AC 1994 Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf ) 41:421–424.
  261. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K 1998 Normalization of serum thyrotropin by mean of radioiodine treatment in subclinical hyperthyroidism: effect of bone loss in postmenopausal women. Clin Endocrinol (Oxf ) 48:285–290.
  262. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y 2000 Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 85:4157–4161.
  263. Tauchmanova` L, Nuzzo V, Del Puente A, Fonderico F, Esposito-Del Puente A, Padulla S, Rossi A, Bifulco G, Lupoli G, Lombardi G 2004 Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas 48:299–306.
  264. Brennan MD, Powell C, Kaufman KR, Sun PC, Bahn RS, Nair KS 2006 The impact of overt and subclinical hyperthyroidism on skeletal muscle. Thyroid 16:375–380.
  265. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP 2010 Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 95:186–193.
  266. Roberts LM, Pattison H, Roalfe A, Franklyn J, Wilson S, Hobbs FD, Parle JV 2006 Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med 145:573–581.
  267. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Fro¨ lich M, Westendorp RG 2004 Thyroid status, disability and cognitive function, and survival in old age. JAMA 292:2591–2599.
  268. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM 2000 Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf ) 53:733–737.
  269. Ceresini G, Lauretani F, Maggio M, Ceda GP, Morganti S, Usberti E, Chezzi C, Valcavi R, Bandinelli S, Guralnik JM, Cappola AR, Valenti G, Ferrucci L 2009 Thyroid function abnormalities and cognitive impairment in elderly people: results of the Invecchiare in Chianti study. J Am Geriatr Soc 57:89–93.
  270. Sawin CT, Geller A, Kaplan MM, Bacharach P, Wilson PW, Hershman JM 1991 Low serum thyrotropin (thyroidstimulating hormone) in older persons without hyperthyroidism. Arch Intern Med 151:165–168.
  271. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA 2001 Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358:861–865.
  272. Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, L'Abbate A, Pingitore A 2007 Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 167:1526–1532.
  273. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, Michelangeli V 2006 Subclinical thyroid dysfunction and blood pressure: a community-based study. Clin Endocrinol (Oxf ) 65:486–491.
  274. Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B 2008 Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 159:329–341.
  275. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, Rodondi N 2008 Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 148:832–845.
  276. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman, JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ 2004 Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291:228–238.
  277. Greenlund LJ, Nair KS, Brennan MD 2008 Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. Endocr Pract 14: 973–978.
  278. Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J 2009 Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol 160:1–8.
  279. Burrow GN, Fisher DA, Larsen PR 1994 Maternal and fetal thyroid function. N Engl J Med 331:1072–1078.
  280. Glinoer D 1997 The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 18:404–433.
  281. Hershman JM 2008 The role of human chorionic gonadotropin as a thyroid stimulator in normal pregnancy. J Clin Endocrinol Metab 93:3305–3306.
  282. Soldin OP, Tractenberg RE, Hollowell JG, Jonklaas J, Janicic N, Soldin SJ 2004 Trimester-specific changes in maternal thyroid hormone, thyrotropin, and thyroglobulin concentrations during gestation: trends and associations across trimesters in iodine sufficiency. Thyroid 14:1084–1090.
  283. Mandel SJ, Spencer CA, Hollowell JG 2005 Are detection and treatment of thyroid insufficiency in pregnancy feasible? Thyroid 15:44–53.
  284. Weeke J, Dybkjaer L, Granlie K, Eskjaer Jensen S, Kjaerulff E, Laurberg P, Magnusson B 1982 A longitudinal study of serum TSH, and total and free iodothyronines during normal pregnancy. Acta Endocrinol (Cph) 101:531–537.
  285. Nelson JC, Wang R, Asher DT, Wilcox RB 2004 The nature of analogue-based free thyroxine estimates. Thyroid 14: 1030–1036.
  286. Lee RH, Spencer CA, Mestman JH, Miller EA, Petrovic I, Braverman LE, Goodwin TM 2009 Free T4 immunoassays are flawed during pregnancy. Am J Obstet Gynecol 200: 260.e1–e6.
  287. Gong Y, Hoffman BR 2008 Free thyroxine reference interval in each trimester of pregnancy determined with the Roche Modular E-170 electrochemiluminescent immunoassay. Clin Biochem 41:902–906.
  288. Silvio R, Swapp KJ, La'ulu SL, Hansen-Suchy K, Roberts WL 2009 Method specific second-trimester reference intervals for thyroid-stimulating hormone and free thyroxine. Clin Biochem 42:750–753.
  289. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG 2006 Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol 107:337–341.
  290. Davis LE, Lucas MJ, Hankins GD, Roark ML, Cunningham FG 1989 Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol 160:63–70.
  291. Millar LK, Wing DA, Leung AS, Koonings PP, Montoro MN, Mestman JH 1994 Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol 84:946–949.
  292. Kriplani A, Buckshee K, Bhargava VL, Takkar D, Ammini AC 1994 Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Bio 54:159–163.
  293. Vos XG, Smit N, Endert E, Tijssen JG, Wiersinga WM 2008 Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Clin Endocrinol (Oxf ) 69:311–317.
  294. Amino N, Tada H, Hidaka Y 1999 Postpartum autoimmune thyroid syndrome: a model of aggravation of autoimmune disease. Thyroid 9:705–713.
  295. Mortimer RH, Tyack SA, Galligan JP, Perry-Keene DA, Tan YM 1990 Graves' disease in pregnancy: TSH receptor binding inhibiting immunoglobulins and maternal and neonatal thyroid function. Clin Endocrinol (Oxf ) 32:141– 152.
  296. Momotani N, Noh JY, Ishikawa N, Ito K 1997 Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab 82:3633–3636.
  297. Laurberg P, Nygaard B, Glinoer D, Grussendorf M, Orgiazzi J 1998 Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Eur J Endocrinol 139:584–586.
  298. Senior B, Chernoff HL 1971 Iodide goiter in the newborn. Pediatrics 47:510–515.
  299. Geelhoed GW 1983 Surgery of the endocrine glands in pregnancy. Clin Obstet Gynecol 26:865–889.
  300. Seeley BL, Burrow GN 1991 Thyrotoxicosis in pregnancy. Endocrinologist 1:409–417.
  301. Chan GW, Mandel SJ 2007 Therapy insight: management of Graves' disease during pregnancy. Nat Clin Pract Endocrinol Metab 3:470–478.
  302. Zakarija M, McKenzie JM 1983 Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab 57:1036–1040.
  303. Polak M, Le Gac I, Vuillard E, Guibourdenche J, Leger J, Toubert ME, Madec AM, Oury JF, Czernichow P, Luton D 2004 Fetal and neonatal thyroid function in relation to maternal Graves' disease. Best Pract Res Clin Endocrinol Metab 18:289–302.
  304. Roti E, Uberti E 2002 Post-partum thyroiditis—a clinical update. Eur J Endocrinol 146:275–279.
  305. Stagnaro-Green A 2002 Clinical review 152: Postpartum thyroiditis. J Clin Endocrinol Metab 87:4042–4047.
  306. Kuijpens JL, Pop VJ, Vader HL, Drexhage HA, Wiersinga WM 1998 Prediction of post partum thyroid dysfunction: can it be improved? Eur J Endocrinol 139:36–43.
  307. Gorman CA 1999 Radioiodine and pregnancy. Thyroid 9: 721–726.
  308. Davanzo R, Rubert L, Oretti C 2008 Meta-variability of advice on drugs in the breastfeeding mother: the example of beta-blockers. Arch Dis Child Fetal Neonatal Ed 93:F249–F250.
  309. Bahn RS 2010 Graves' ophthalmopathy. New Engl J Med 362:726–738.
  310. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R 1989 Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 73:639–644.
  311. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L 1997 Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf ) 47:9–14.
  312. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Curro` N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marino` M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 18:333–346.
  313. de Juan E Jr., Hurley DP, Sapira JD 1980 Racial differences in normal values of proptosis. Arch Intern Med 140:1230–1231.
  314. Sarinnapakorn V, Sridama V, Sunthornthepvarakul T 2007 Proptosis in normal Thai samples and thyroid patients. J Med Assoc Thai 90:679–683.
  315. Tsai CC, Kau HC, Kau SC, Hsu WM 2006 Exophthalmos of patients with GD in Chinese of Taiwan. Eye (Lond) 20:569–573.
  316. Yeatts RP 2005 Quality of life in patients with Graves ophthalmopathy. Trans Am Ophthalmol Soc 103:368–411.
  317. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM 1998 Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol 82:773–779.
  318. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A 1998 Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338:73–78.
  319. Tallstedt L, Lundell G, Tørring O, Wallin G, Ljunggren JG, Blomgren H, Taube A 1992 Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 326:1733–1738.
  320. Eckstein AK, Plicht M, Lax H, Neuha¨user M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG 2006 Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464–3470.
  321. Tallstedt L, Lundell G, Blomgren H, Bring J 1994 Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130:494–497.
  322. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R 1990 Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 150:1098–1101.
  323. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J 2005 A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy. J Clin Endocrinol Metab 90:5321–5323.
  324. Sridama V, DeGroot LJ 1989 Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 87:70–73.
  325. Pfeilschifter J, Ziegler R 1996 Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf ) 45:477–481.
  326. EisenbergMJ, Filion KB, Yavin D, Be´lisle P,Mottillo S, Joseph L, Gervais A, O'Loughlin J, Paradis G, Rinfret S, Pilote L 2008 Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 179:135–144.
  327. Fiore MC, Jaen CR 2008 A clinical blueprint to accelerate the elimination of tobacco use. JAMA 299:2083–2085.
  328. Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L 2010 Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 95:1333–1337.
  329. Fernández Sánchez JR, Rosell Pradas J, Carazo Martinez O, Torres Vela E, Escobar Jimenez F, Garbin Fuentes I, Vara Thorbeck R 1993 Graves’ ophthalmopathy after subtotal thyroidectomy and radioiodine therapy. Br J Surg 80:1134–1136..
  330. Järhult J, Rudberg C, Larsson E, Selvander H, Sjövall K, Winsa B, Rastad J, Karlsson FA; TEO Study Group 2005 Graves’ disease with moderate-severe endocrine ophthalmopathy-long term results of a prospective, randomized study of total or subtotal thyroid resection. Thyroid 15:1157–1164..
  331. Domosławski P, Łukieńczuk T, Forkasiewicz Z, Balcerzak W, Bednarz W, Dawiskiba1 J, Krawczyk Z, Wojtczak B, Olewiński R, Podhorska-Okołów M 2007 Influence of total thyroidectomy on orbital opthalmopathy and levels of antithyroid antibodies in patients with Graves’ disease. Polski Przeglad Chirurgiczny 79:303–312..
  332. Vannucchi G, Campi I, Covelli D, Dazzi D, Curro` N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M 2009 Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 94:3381–3386.
  333. Surks MI, Sievert R 1995 Drugs and thyroid function. N Engl J Med 333:1688–1694.
  334. Hintze G, Blombach O, Fink H, Burkhardt U, Kobberling J 1999 Risk of iodine-induced thyrotoxicosis after coronary angiography: an investigation in 788 unselected subjects. Eur J Endocrinol 140:264–267.
  335. Martin FI, Tress BW, Colman PG, Deam DR 1993 Iodineinduced hyperthyroidism due to nonionic contrast radiography in the elderly. Am J Med 95:78–82.
  336. Conn JJ, Sebastian MJ, Deam D, Tam M, Martin FI 1996 A prospective study of the effect of nonionic contrast media on thyroid function. Thyroid 6:107–110.
  337. Roti E, Gardini E, Minelli R, Bianconi L, Salvi M, Gavaruzzi G, Braverman LE 1993 Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism. J Clin Endocrinol Metab 76:928–932.
  338. Fradkin JE, Wolff J 1983 Iodide-induced thyrotoxicosis. Medicine (Baltimore) 62:1–20.
  339. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E 2004 Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 89:3656–3661.
  340. Prummel MF, Laurberg P 2003 Interferon-alpha and autoimmune thyroid disease. Thyroid 13:547–551.
  341. Koh LK, Greenspan FS, Yeo PP 1997 Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 7:891–896.
  342. Basaria S, Cooper DS 2005 Amiodarone and the thyroid. Am J Med 118:706–714.
  343. Iudica-Souza C, Burch HB 1999 Amiodarone-induced thyroid dysfunction. Endocrinologist 9:216–227.
  344. Martino E, Safran M, Aghini-Lombardi F, Rajatanavin R, Lenziardi M, Fay M, Pacchiarotti A, Aronin N, Macchia E, Haffajee C, et al. 1984 Enviromental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Int Med 101:28–34.
  345. Eaton SE, Euinton HA, Newman CM, Weetman AP, Bennet WM 2002 Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf ) 56:33–38.
  346. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E 1996 Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab 81:2930–2933.
  347. Erdogan MF, Gulec S, Tutar E, Baskal N, Erdogan G 2003 A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis. Thyroid 13:205–209.
  348. Houghton SG, Farley DR, Brennan MD, van Heerden JA, Thompson GB, Grant CS 2004 Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg 28:1083–1087.
  349. Williams M, Lo Gerfo P 2002 Thyroidectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: a review and description of the technique. Thyroid 12:523–525.
  350. Nikolai TF, Coombs GJ, McKenzie AK, Miller RW, Weir GJ Jr. 1982 Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med 142:2281–2283.
  351. Sicilia V, Mezitis S 2006 A case of acute suppurative thyroiditis complicated by thyrotoxicosis. J Endocrinol Invest 29:997–1000.
  352. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD 1996 Thyrotropin-secreting pituitary tumors. Endocr Rev 17:610–638.
  353. Ross DS 1998 Syndromes of thyrotoxicosis with low radioactive iodine uptake. Endocrinol Metab Clin North Am 27:169–185.
  354. Kung AW, Ma JT, Wang C, Young RT 1990 Hyperthyroidism during pregnancy due to coexistence of struma ovarii and Graves' disease. Postgrad Med J 66:132–133.
  355. Hershman JM 1999 Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Thyroid 9:653–657.
  356. Goodarzi MO, Van Herle AJ 2000 Thyrotoxicosis in a male patient associated with excess human chorionic gonadotropin production by germ cell tumor. Thyroid 10:611– 619.
  357. Hedberg CW, Fishbein DB, Janssen RS, Meyers B, McMillen JM, MacDonald KL, White KE, Huss LJ, Hurwitz ES, Farhie JR, et al. 1987 An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med 316:993–998.
  358. Kasagi K, Takeuchi R, Miyamoto S, Misaki T, Inoue D, Shimazu A, Mori T, Konishi J 1994 Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases. Clin Endocrinol (Oxf ) 40:429–434.

Address correspondence to:
Rebecca S. Bahn, M.D.
Division of Endocrinology, Metabolism, and Nutrition
Mayo Clinic
200 First St. SW
Rochester, MN 55905

E-mail: bahn.rebecca@mayo.edu